SITE002-0270

completed

Study: A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer Phase III · Site: SITE002 (USA) (Dr. Nolan) · consented 2023-01-10

Adverse events

Serious AEs

Open data queries

Luna dropout signal

–

Adverse events

mild assessed 2026-08-18

Grade 1 Neutropenia — outcome: RECOVERED/RESOLVED; onset 2023-03-21 (study day 52); relationship: not assessed

severe serious assessed 2026-08-18

Grade 3 Stomatitis — outcome: RECOVERED/RESOLVED; onset 2023-04-15 (study day 77); relationship: N; serious criteria: hospitalization

mild assessed 2026-08-18

Grade 1 Nausea — outcome: RECOVERED/RESOLVED; onset 2023-04-21 (study day 83); relationship: not assessed

severe serious assessed 2026-08-18

Grade 4 Stomatitis — outcome: RECOVERED/RESOLVED; onset 2023-09-17 (study day 232); relationship: not assessed; serious criteria: life-threatening

mild assessed 2026-08-18

Grade 1 Anaemia — outcome: RECOVERED/RESOLVED; onset 2023-10-09 (study day 254); relationship: N

mild assessed 2026-08-18

Grade 1 Vomiting — outcome: RECOVERED/RESOLVED; onset 2023-10-23 (study day 268); relationship: not assessed

Data queries

No data queries.

☾ Luna engagement

This participant doesn't use Luna.